C149851_DHSC: OHID: Anorectal malformations Evidence Map

Department of Health and Social Care (London)contractContracts FinderRef CF-1441400D0O000000rwimUAASME suitablecomplete

Estimated value

£19k

Awarded value

£17k

Awarded 20 Mar 2023

Suppliers

1

Lots

1

1 awarded

Published

24 Mar 2023

Deadline 08 Mar 2023

Other contracts from Department of Health and Social Care (London)· 10

Most recent notices published by the same contracting authority.

View buyer profile →
TitleTypeValuePublished
De-risking the Uk's antibiotic supply chain 2026contract£80k21 Jan 2026
Children and Young People Mental Health Early Intervention Hubscall off£5.5m10 Jan 2025
HPV Self-sampling cost effectiveness modelcall off£300k14 Oct 2024
DHSC: SC&I: Lampard Inquiry Transcription, Translation and Interpretationcontract£39k01 Oct 2024
Opportunity awardedcontract£100k09 Aug 2024
DHSC_PCP_HPV Self-sampling Cost Effectiveness Modelcontract15 Jul 2024
Screening Programme FY2024/25call off12 Jun 2024
Cost-effectiveness model of prostate cancer screening 24/25contract£100k07 Mar 2024
DHSC: ASC: Leadership Development Programme for ASCWcontract30 Oct 2023
OHID: MHISS - Modernising Health Intelligence Systemscall off£661k02 Oct 2023

Other contracts awarded to COSTELLO MEDICAL CONSULTING LIMITED· 10

Cross-buyer view of this supplier's public-sector wins.

View supplier profile →
TitleTypeValuePublished
Health Economics Feasibility Study- Specialised Commissioningcontract£24k17 Oct 2023
DHSC: OHID: Metachromatic Leukodystrophy (MLD) Evidence Mapcontract£16k20 Mar 2023
Consultancy Services for Population Health Programmecontract£44k29 Nov 2022
Evidence Map on Screening for Cytomegaloviruscontract£50k18 Jun 2021
PHE - Corporate - Evidence Map on Biotinidase Deficiencycontract£6k09 Jun 2021
PHE - Corporate - Asymptomatic Bacteriuria Screening in Pregnancycontract£81k26 May 2021
PHE - Corporate - Evidence Map on Neuronal Ceroid Lipofuscinosis Type 2contract£11k21 Apr 2021
PHE - Corporate - Screening for Duchenne Muscular Dystrophycontract£15k31 Mar 2021
PHE - Corporate - A Clinical and Cost Effectiveness Model on Formalising New-born Screening for β-thalassaemia Majorcontract£81k03 Nov 2020
PHE - Corporate - Ultrasound Screening for Fetal Presentation at 36 Weekscontract£11k02 Sept 2020